«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

30卷

期数:

2024年05期

页码:

405-409,421

栏目:

肿瘤疾病专题

出版日期:

2024-09-25

文章信息/Info

Title:

GYS1 promotes hepatocellular carcinoma progression by activating the NF-κB pathway

文章编号:

1006-8147（2024）05-0405-06

作者:

王金伟; 张立萍; 胡石甫; 黄涛; 刘汉博

（天津市西青医院普外科，天津300380）

Author(s):

WANG Jinwei; ZHANG Liping; HU Shifu; HUANG Tao; LIU Hanbo

（Department of General Surgery，Tianjin Xiqing Hospital，Tianjin 300380，China）

关键词:

肝细胞癌; 糖原合成酶1; NF-κB

Keywords:

hepatocellular carcinoma; glycogen synthase1; NF-κB

分类号:

R735.7

DOI:

10.20135/j.issn.1006-8147.2024.05.0405

文献标志码:

A

摘要:

目的：探究糖原合成酶1（GYS1）在原发性肝细胞癌（HCC）进展中的作用。方法：基于GEPIA数据库分析GYS1在肿瘤与癌旁组织的表达差异。从天津市西青医院取20例HCC临床样本。采用RT-PCR、Western印迹及免疫组化验证GYS1基因在肿瘤与癌旁组织的表达差异。对于HCC细胞系，分别转染过表达GYS1质粒及siRNA，采用CCK8、EDU以及划痕实验验证过表达或敲除GYS1后HCC细胞增殖及迁移能力变化。采用Western印迹实验验证过表达或敲除GYS1后核因子（NF）-κB通路的变化。结果：与癌旁组织相比，HCC组织中GYS1表达显著上调（F=30.23，P<0.001）；与正常肝细胞相比，肿瘤细胞系中GYS1明显高表达（F=287.35，P<0.001）。基于数据库分析表明，过表达GYS1的HCC患者预后较差（P<0.05）。过表达GYS1在体外促进HCC细胞增殖（F=58.67，P<0.01）及迁移（F=67.34，P<0.01）；而敲除GYS1则抑制HCC细胞增殖（F=66.32，P<0.01）及迁移（F=79.24，P<0.01）。RT-PCR及Western印迹结果证实，过表达GYS1可激活NF-κB通路，而敲除GYS1可抑制GYS1通路。结论：HCC组织中GYS1表达量明显升高，并且过表达GYS1，可通过激活NF-κB通路促进HCC进展。

Abstract:

Objective：To investigate the role of glycogen synthase1（GYS1） in the process of disease progression in hepatocellular carcinoma（HCC）. Methods：Differential expression of GYS1 in tumor and paracancerous tissues was analyzed based on GEPIA database. A total of clinical samples of primary HCC were obtained from Xiqing Hospital in Tianjin. RT-PCR，Western blotting and immunohistochemistry were used to verify the expression difference of GYS1 gene in tumor and paracancer tissues. For HCC lines，overexpression of GYS1 plasmid and siRNA were transfected，and CCK8，EDU and scratch assay were used to verify the changes in the proliferation and migration ability of HCC after overexpression or knockdown of GYS1. Western blotting was used to verify the changes of nuclear factor （NF）-κB pathway after overexpression or knockdown of GYS1. Results：Compared with paraneoplastic tissues，GYS1 expression was significantly upregulated in HCC tissues（F=30.23，P<0.001）. Compared with normal hepatocytes，GYS1 was significantly overexpressed in tumor cell lines（F=287.35，P<0.001）. Database-based analysis showed that patients with hepatocellular carcinoma overexpressing GYS1 had a poorer prognosis（P<0.05）. Overexpression of GYS1 promoted the proliferation（F=58.67，P<0.01） and migration（F=67.34，P<0.01） of HCC cells in vitro，whereas knockdown of GYS1 inhibited the proliferation（F=66.32，P<0.01）and migration（F=79.24，P<0.01） of HCC cells.RT-PCR and Western blotting results confirmed that overexpression of GYS1 activated the NF-κB pathway，whereas knockdown of GYS1 inhibited the NF-κB pathway. Conclusion：The expression of GYS1 in HCC tissues is significantly increased，and overexpression of GYS1 can promote the malignant progression of HCC by activating the NF-κB pathway.

参考文献/References:

[1] FERLAY J，SOERJOMATARAM I，DIKSHIT R，et al. Cancer incidence and mortality worldwide：sources，methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer，2015，136（5）：E359-E386.
[2] WANG G，LI J，BOJMAR L，et al. Tumour extracellular vesicles and particles induce liver metabolic dysfunction[J]. Nature，2023，618（7964）：374-382.
[3] BIAN X L，CHEN H Z，YANG P B，et al. Nur77 suppresses hepatocellular carcinoma via switching glucose metabolism toward gluconeogenesis through attenuating phosphoenolpyruvate carboxykinasesumoylation[J]. Nat Commun，2017，8：14420.
[4] ROACH P J，DEPAOLI-ROACH A A，HURLEY T D，et al. Glycogen and its metabolism：some new developments and old themes[J]. Biochem J，2012，441（3）：763-787.
[5] BARENS P J，KAEIN M. Nuclear factor-kappaB：a pivotal transcription factor in chronic inflammatory diseases[J]. N Engl J Med，1997，336（15）：1066-1071.
[6] KUO W Y，HWU L，WU C Y，et al. STAT3/NF-κB-regulated lentiviral TK/GCV suicide gene therapy for cisplatin-resistant triple-negative breast cancer[J]. Theranostics，2017，7（3）：647-663.
[7] YU C，CHEN S，GUO Y，et al. Oncogenic TRIM31 confers gemcitabine resistance in pancreatic cancer via activating the NF-κB signaling pathway[J]. Theranostics，2018，8（12）：3224-3236.
[8] YAO F，DENG Y，ZHAO Y，et al. A targetable LIFR-NF-κB-LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis[J]. Nat Commun，2021，12（1）：7333.
[9] LIU J，WU Z，HAN D，et al. Mesencephalic astrocyte-derived neurotrophic factor inhibits liver cancer through small ubiquitin-related modifier （SUMO） ylation-related suppression of NF-κB/snail signaling pathway and epithelial-mesenchymal transition[J]. Hepatology，2020，71（4）：1262-1278.
[10] ROUSSET M，ZWEIBAUM A，FOGH J. Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins[J]. Cancer Res，1981，41（3）：1165-1170.
[11] LEA M A，MURPHY P，MORRIS H P. Glycogen metabolism in regenerating liver and liver neoplasms[J]. Cancer Res，1972，32（1）：61-66.
[12] CHEN S L，HUANG Q S，HUANG Y H，et al. GYS1 induces glycogen accumulation and promotes tumor progression via the NF-κB pathway in clear cell renal carcinoma[J]. Theranostics，2020，10（20）：9186-9199.
[13] HUANG Q，LI J，XING J，et al. CD147 promotes reprogramming of glucose metabolism and cell proliferation in HCC cells by inhibiting the p53-dependent signaling pathway[J]. J Hepatol，2014，61（4）：859-866.
[14] CHAO T，ZHOU X，CAO B，et al. Pleckstrin homology domain-containing protein PHLDB3 supports cancer growth via a negative feedback loop involving p53[J]. Nat Commun，2016，7：13755.
[15] WAN F，ANDERSON D E，BARNITZ R A，et al. Ribosomal protein S3：a KH domain subunit in NF-kappaB complexes that mediates selective gene regulation[J]. Cell，2007，131（5）：927-939.
[16] JIANG P，DU W，WANG X，et al. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase[J]. Nat Cell Biol，2011，13（3）：310-316.
[17] MORANDY A，INDRACCOLO S. Linking metabolic reprogramming to therapy resistance in cancer[J]. Biochim Biophys Acta Rev Cancer，2017，1868（1）：1-6.

相似文献/References:

[1]周冷潇,韩 涛.慢性乙型病毒性肝炎肝硬化发生肝细胞癌的危险因素分析[J].天津医科大学学报,2017,23(03):214.
　ZHOU Leng-xiao,HAN Tao.Risk factors of hepatocellular carcinoma in patients with hepatitis B virus-related liver cirrhosis[J].Journal of Tianjin Medical University,2017,23(05):214.
[2]周冷潇,韩 涛,刘 芳.无创肝纤维化指标结合甲胎蛋白对乙型肝炎相关肝细胞癌的评估[J].天津医科大学学报,2017,23(05):415.
　ZHOU Leng-xiao,HAN Tao,LIU Fang.Assessment of non-invasive fibrosis indexes with alpha-fetoprotein?for? hepatitis B virus-related hepatocellular carcinoma[J].Journal of Tianjin Medical University,2017,23(05):415.
[3]张自立,石文霞,李 霖,等.肝癌血清中miRNA-183的表达及临床意义[J].天津医科大学学报,2017,23(06):519.
　ZHANG Zi-li,?SHI Wen-xia,LI Lin,et al.Expression and significance of serum microRNA-183 in hepatocellular carcinoma[J].Journal of Tianjin Medical University,2017,23(05):519.
[4]侯振宇,孔银龙,孙 林,等.92例晚期肝细胞癌患者肝切除预后及危险因素分析[J].天津医科大学学报,2018,24(05):425.
　HOU Zhen-yu,KONG Yin-long,SUN Lin,et al.Prognosis and survival risk factors for 92 advanced hepatocellular carcinoma patients after hepatectomy[J].Journal of Tianjin Medical University,2018,24(05):425.
[5]胡 源,许戈良,荚卫东,等.C1QL1蛋白在原发性肝细胞癌中的表达及其临床意义[J].天津医科大学学报,2019,25(04):329.
　HU Yuan,XU Ge-liang,JIA Wei-dong,et al.Expressions of C1QL1 protein inprimaryhepatocellular carcinoma and its clinical significance[J].Journal of Tianjin Medical University,2019,25(05):329.
[6]张萃萃,邓为民.基因表达谱分析肝细胞癌的特征基因[J].天津医科大学学报,2020,26(06):514.
　ZHANG Cui-cui,DENG Wei-min.Gene expression profiling reveals important characteristic genes in hepatocellular carcinoma[J].Journal of Tianjin Medical University,2020,26(05):514.
[7]张杨,游阿彬,齐寒,等.负载化疗药物的外泌体对肝癌的靶向治疗研究[J].天津医科大学学报,2021,27(03):229.
　ZHANG Yang,YOU A-bin,QI Han,et al.Tumor-derived exosomes mediate targeted therapy in hepatocellular carcinoma mice[J].Journal of Tianjin Medical University,2021,27(05):229.
[8]王凤松,朱刘洋,白易,等.基于肿瘤突变负荷构建肝细胞癌风险评分预后模型[J].天津医科大学学报,2022,28(01):20.
　WANG Feng-song,ZHU Liu-yang,BAI Yi,et al.Identification of a risk score prognostic model of hepatocellular carcinoma based on tumor mutation burden[J].Journal of Tianjin Medical University,2022,28(05):20.
[9]赵耕,张盈莹,卓永,等.藏区慢性乙型肝炎患者使用PAGE-B模型对肝细胞癌的风险预测研究[J].天津医科大学学报,2022,28(06):654.
　ZHAO Geng,ZHANG Ying-ying,ZHUO Yong,et al.Risk prediction of hepatocellular carcinoma using the PAGE-B model in Tibetan patients with chronic hepatitis B[J].Journal of Tianjin Medical University,2022,28(05):654.
[10]张华,范松,刘冀琴,等.miR-129-5p通过靶向SALL4抑制肝癌细胞增殖、迁移和侵袭的实验研究[J].天津医科大学学报,2024,30(01):11.[doi:10.20135/j.issn.1006-8147.2024.01.0011]
　ZHANG Hua,FAN Song,LIU Jiqin,et al.The experimental study of miR-129-5p inhibiting proliferation， migration， and invasion of hepatocellular carcinoma by targeting to SALL4[J].Journal of Tianjin Medical University,2024,30(05):11.[doi:10.20135/j.issn.1006-8147.2024.01.0011]

备注/Memo

备注/Memo:

作者简介 王金伟（1983-），男，主治医师，学士，研究方向：肝胆外科疾病；通信作者：刘汉博，E-mail：lhb1236541@163.com。

常用功能

更新日期/Last Update: 2024-09-20